Literature DB >> 11120944

Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.

K A Marr1, C N Lyons, K Ha, T R Rustad, T C White.   

Abstract

The development of azole resistance in Candida albicans is most problematic in patients with AIDS who receive long courses of drug for therapy or prevention of oral candidiasis. Recently, the rapid development of resistance was noted in other immunosuppressed patients who developed disseminated candidiasis despite fluconazole prophylaxis. One of these series of C. albicans isolates became resistant, with an associated increase in mRNA specific for a CDR ATP-binding cassette transporter efflux pump (K. A. Marr, C. N. Lyons, T. R. Rustad, R. A. Bowden, and T. C. White, Antimicrob. Agents Chemother. 42:2584-2589, 1998). Here we study this series of C. albicans isolates further and examine the mechanism of azole resistance in a second series of C. albicans isolates that caused disseminated infection in a recipient of bone marrow transplantation. The susceptible isolates in both series become resistant to fluconazole after serial growth in the presence of drug, while the resistant isolates in both series become susceptible after serial transfer in the absence of drug. Population analysis of the inducible, transiently resistant isolates reveals a heterogeneous population of fluconazole-susceptible and -resistant cells. We conclude that the rapid development of azole resistance occurs by a mechanism that involves selection of a resistant clone from a heterogeneous population of cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120944      PMCID: PMC90239          DOI: 10.1128/AAC.45.1.52-59.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

Authors:  K Sieradzki; R B Roberts; S W Haber; A Tomasz
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

2.  Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  B Moreira; S Boyle-Vavra; B L deJonge; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors:  J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

Review 4.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.

Authors:  T C White; M A Pfaller; M G Rinaldi; J Smith; S W Redding
Journal:  Oral Dis       Date:  1997-05       Impact factor: 3.511

6.  High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance.

Authors:  S A Yoon; J A Vazquez; P E Steffan; J D Sobel; R A Akins
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

7.  Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.

Authors:  K A Marr; T C White; J A van Burik; R A Bowden
Journal:  Clin Infect Dis       Date:  1997-10       Impact factor: 9.079

8.  Evolution of drug resistance in experimental populations of Candida albicans.

Authors:  L E Cowen; D Sanglard; D Calabrese; C Sirjusingh; J B Anderson; L M Kohn
Journal:  J Bacteriol       Date:  2000-03       Impact factor: 3.490

Review 9.  Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

10.  Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

Authors:  K A Marr; C N Lyons; T R Rustad; R A Bowden; T C White; T Rustad
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  38 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

2.  Transcriptional profiling of azole-resistant Candida parapsilosis strains.

Authors:  A P Silva; I M Miranda; A Guida; J Synnott; R Rocha; R Silva; A Amorim; C Pina-Vaz; G Butler; A G Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

3.  Susceptibility of Candida species to photodynamic effects of photofrin.

Authors:  Joseph M Bliss; Chad E Bigelow; Thomas H Foster; Constantine G Haidaris
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

4.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

6.  Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2008-05       Impact factor: 4.076

Review 7.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 8.  The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen.

Authors:  Joachim Morschhäuser
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

9.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.

Authors:  John E Bennett; Koichi Izumikawa; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.